Three‐year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post‐marketing surveillance study-Reference-Cited by-同舟云学术

Three‐year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post‐marketing surveillance study

Published:2018-08-05 Issue:2 Volume:11 Page:O152-O161
ISSN:1757-5664
Container-title:LUTS: Lower Urinary Tract Symptoms
language:en
Short-container-title:Lower Urinary Tract Symptoms

Author:

Kato Daisuke¹,Tabuchi Hiromi¹,Uno Satoshi²

Affiliation:

1. Medical Science, Medical Affairs, Astellas Pharma Inc. Tokyo Japan

2. Japan–Asia Data Science, Development, Astellas Pharma Inc. Tokyo Japan

Funder

Astellas Pharma Global Development

Publisher

Wiley

Subject

Urology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/luts.12237

Reference37 articles.

1. An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder

2. The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis

4. Persistence and compliance with medication management in the treatment of overactive bladder

5. Antimuscarinics and overactive bladder: other mechanism of action

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of urinary retention caused by selective β3-adrenoceptor agonists using the Japanese Adverse Drug Event Report database (JADER);PHARMAZIE;2023

2. Treating overactive bladder with percutaneous tibial nerve stimulation;Journal of the American Academy of Physician Assistants;2021-12

3. Costoefectividad del régimen combinado de mirabegron/solifenacina en el tratamiento del síndrome de vejiga hiperactiva en Colombia;Revista Urología Colombiana / Colombian Urology Journal;2021-12

4. The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications;Neurourology and Urodynamics;2021-10-31

5. The 1‐year continuation rate and discontinuation factors of vibegron and mirabegron: A retrospective comparative study in a rehabilitation hospital in Japan;LUTS: Lower Urinary Tract Symptoms;2021-05-24